SYT-510
Endocannabinoid reuptake inhibitor under development for psychiatric disorders
From Wikipedia, the free encyclopedia
SYT-510 is an endocannabinoid reuptake inhibitor, or "selective endocannabinoid reuptake inhibitor" ("SERI"), which is under development for the treatment of psychiatric disorders, anxiety disorders, mood disorders, and traumatic stress disorders.[2][1][3][4][5] It is said to mildly and selectively increase levels of endocannabinoids like anandamide via inhibition of a newly identified biological target.[3][5][2] As of September 2025, the drug is in phase 1 clinical trials for psychiatric disorders and an unspecified indication, whereas no recent development has been reported for anxiety disorders, mood disorders, or post-traumatic stress disorder (PTSD).[2][1][5][4] It is under development by a pharmaceutical company called Synendos Therapeutics.[2][1][3][4]
| Clinical data | |
|---|---|
| Other names | SYT510 |
| Routes of administration | Oral[1] |
| Drug class | Endocannabinoid reuptake inhibitor[2] |
